Sodium MRI of multiple sclerosis

NMR in Biomedicine

Volumn 29, Issue 2, 2016, Pages 153-161

  Petracca, Maria ^a,b   Fleysher, Lazar ^a   Oesingmann, Niels ^c   Inglese, Matilde ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^c Siemens HealthCare   (United States)

Author keywords

Axonal degeneration; Multiple sclerosis; Sodium MRI

Indexed keywords

IMAGING TECHNIQUES; MAGNETIC RESONANCE IMAGING; NEURODEGENERATIVE DISEASES; NONINVASIVE MEDICAL PROCEDURES;

AXONAL DEGENERATION; DISEASE PROGRESSION; FUTURE PERSPECTIVES; MULTIPLE SCLEROSIS; NONINVASIVE METHODS; SODIUM MRI; STRUCTURAL INFORMATION; TREATMENT OUTCOMES;

SODIUM;

SODIUM; SODIUM 23; SODIUM CHANNEL;

DIFFUSION WEIGHTED IMAGING; HUMAN; IMAGE ANALYSIS; MULTIPLE SCLEROSIS; NERVE DEGENERATION; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; SODIUM CELL LEVEL; BRAIN MAPPING; METABOLISM; PROCEDURES;

BRAIN MAPPING; HUMANS; MAGNETIC RESONANCE IMAGING; MULTIPLE SCLEROSIS; SODIUM; SODIUM ISOTOPES;

EID: 84954394896     PISSN: 09523480     EISSN: 10991492     Source Type: Journal    
DOI: 10.1002/nbm.3289     Document Type: Review

References (77)

1. Compston A, Coles A. Multiple sclerosis. Lancet 2008; 372(9648): 1502-1517.
2. International Multiple Sclerosis Genetics C, Beecham AH, Patsopoulos NA, Xifara DK, Davis MF, Kemppinen A, Cotsapas C, Shah TS, Spencer C, Booth D, Goris A, Oturai A, Saarela J, Fontaine B, Hemmer B, Martin C, Zipp F, D'Alfonso S, Martinelli-Boneschi F, Taylor B, Harbo HF, Kockum I, Hillert J, Olsson T, Ban M, Oksenberg JR, Hintzen R, Barcellos LF, Wellcome Trust Case Control C, International IBDGC, Agliardi C, Alfredsson L, Alizadeh M, Anderson C, Andrews R, Sondergaard HB, Baker A, Band G, Baranzini SE, Barizzone N, Barrett J, Bellenguez C, Bergamaschi L, Bernardinelli L, Berthele A, Biberacher V, Binder TM, Blackburn H, Bomfim IL, Brambilla P, Broadley S, Brochet B, Brundin L, Buck D, Butzkueven H, Caillier SJ, Camu W, Carpentier W, Cavalla P, Celius EG, Coman I, Comi G, Corrado L, Cosemans L, Cournu-Rebeix I, Cree BA, Cusi D, Damotte V, Defer G, Delgado SR, Deloukas P, di Sapio A, Dilthey AT, Donnelly P, Dubois B, Duddy M, Edkins S, Elovaara I, Esposito F, Evangelou N, Fiddes B, Field J, Franke A, Freeman C, Frohlich IY, Galimberti D, Gieger C, Gourraud PA, Graetz C, Graham A, Grummel V, Guaschino C, Hadjixenofontos A, Hakonarson H, Halfpenny C, Hall G, Hall P, Hamsten A, Harley J, Harrower T, Hawkins C, Hellenthal G, Hillier C, Hobart J, Hoshi M, Hunt SE, Jagodic M, Jelcic I, Jochim A, Kendall B, Kermode A, Kilpatrick T, Koivisto K, Konidari I, Korn T, Kronsbein H, Langford C, Larsson M, Lathrop M, Lebrun-Frenay C, Lechner-Scott J, Lee MH, Leone MA, Leppa V, Liberatore G, Lie BA, Lill CM, Linden M, Link J, Luessi F, Lycke J, Macciardi F, Mannisto S, Manrique CP, Martin R, Martinelli V, Mason D, Mazibrada G, McCabe C, Mero IL, Mescheriakova J, Moutsianas L, Myhr KM, Nagels G, Nicholas R, Nilsson P, Piehl F, Pirinen M, Price SE, Quach H, Reunanen M, Robberecht W, Robertson NP, Rodegher M, Rog D, Salvetti M, Schnetz-Boutaud NC, Sellebjerg F, Selter RC, Schaefer C, Shaunak S, Shen L, Shields S, Siffrin V, Slee M, Sorensen PS, Sorosina M, Sospedra M, Spurkland A, Strange A, Sundqvist E, Thijs V, Thorpe J, Ticca A, Tienari P, van Duijn C, Visser EM, Vucic S, Westerlind H, Wiley JS, Wilkins A, Wilson JF, Winkelmann J, Zajicek J, Zindler E, Haines JL, Pericak-Vance MA, Ivinson AJ, Stewart G, Hafler D, Hauser SL, Compston A, McVean G, De Jager P, Sawcer SJ, McCauley JL. Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis. Nat. Genet. 2013; 45(11): 1353-1360.
3. Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M, Fujihara K, Havrdova E, Hutchinson M, Kappos L, Lublin FD, Montalban X, O'Connor P, Sandberg-Wollheim M, Thompson AJ, Waubant E, Weinshenker B, Wolinsky JS. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann. Neurol. 2011; 69(2): 292-302.
4. Lublin FD, Reingold SC, Cohen JA, Cutter GR, Sorensen PS, Thompson AJ, Wolinsky JS, Balcer LJ, Banwell B, Barkhof F, Bebo B, Jr, Calabresi PA, Clanet M, Comi G, Fox RJ, Freedman MS, Goodman AD, Inglese M, Kappos L, Kieseier BC, Lincoln JA, Lubetzki C, Miller AE, Montalban X, O'Connor PW, Petkau J, Pozzilli C, Rudick RA, Sormani MP, Stuve O, Waubant E, Polman CH. Defining the clinical course of multiple sclerosis: the 2013 revisions. Neurology 2014; 83(3): 278-286.
5. Waxman SG. Mechanisms of disease: sodium channels and neuroprotection in multiple sclerosis-current status. Nat. Clin. Pract. Neurol. 2008; 4(3): 159-169.
6. Trapp BD, Peterson J, Ransohoff RM, Rudick R, Mork S, Bo L. Axonal transection in the lesions of multiple sclerosis. N. Engl. J. Med. 1998; 338(5): 278-285.
7. Nave KA, Trapp BD. Axon-glial signaling and the glial support of axon function. Annu. Rev. Neurosci. 2008; 31: 535-561.
8. Dutta R, McDonough J, Yin X, Peterson J, Chang A, Torres T, Gudz T, Macklin WB, Lewis DA, Fox RJ, Rudick R, Mirnics K, Trapp BD. Mitochondrial dysfunction as a cause of axonal degeneration in multiple sclerosis patients. Ann. Neurol. 2006; 59(3): 478-489.
9. Campbell GR, Ziabreva I, Reeve AK, Krishnan KJ, Reynolds R, Howell O, Lassmann H, Turnbull DM, Mahad DJ. Mitochondrial DNA deletions and neurodegeneration in multiple sclerosis. Ann. Neurol. 2011; 69(3): 481-492.
10. Cambron M, D'Haeseleer M, Laureys G, Clinckers R, Debruyne J, De Keyser J. White-matter astrocytes, axonal energy metabolism, and axonal degeneration in multiple sclerosis. J. Cereb. Blood Flow Metab. 2012; 32(3): 413-424.
11. Pitt D, Werner P, Raine CS. Glutamate excitotoxicity in a model of multiple sclerosis. Nat. Med. 2000; 6(1): 67-70.
12. Lassmann H, van Horssen J, Mahad D. Progressive multiple sclerosis: pathology and pathogenesis. Nat. Rev. Neurol. 2012; 8(11): 647-656.
13. Lassmann H. Mechanisms of white matter damage in multiple sclerosis. Glia 2014; 62(11): 1816-1830.
14. Smith KJ. Sodium channels and multiple sclerosis: roles in symptom production, damage and therapy. Brain Pathol. 2007; 17(2): 230-242.
15. Moll C, Mourre C, Lazdunski M, Ulrich J. Increase of sodium channels in demyelinated lesions of multiple sclerosis. Brain Res. 1991; 556(2): 311-316.
16. 2+ exchanger. Proc. Natl. Acad. Sci. U. S. A. 2004; 101(21): 8168-8173.
17. + channel beta2 subunits is neuroprotective in a mouse model of multiple sclerosis. Mol. Cell. Neurosci. 2009; 40(2): 143-155.
18. Boada FEGJ, Shen GX, Chang SY, Thulborn KR. Fast three dimensional sodium imaging. Magn. Reson. Med. 1997; 37: 706-715.
19. Thulborn KR, Gindin TS, Davis D, Erb P. Comprehensive MR imaging protocol for stroke management: tissue sodium concentration as a measure of tissue viability in nonhuman primate studies and in clinical studies. Radiology 1999; 213(1): 156-166.
20. Winter PM, Bansal N. Triple-quantum-filtered (23)Na NMR spectroscopy of subcutaneously implanted 9l gliosarcoma in the rat in the presence of TmDOTP(5-1). J. Magn. Reson. 2001; 152(1): 70-78.
21. - as an NMR shift reagent and extracellular marker. J. Appl. Physiol. 1998; 85(5): 1806-1812.
22. Woodward DL, Reed DJ, Woodbury DM. Extracellular space of rat cerebral cortex. Am. J. Physiol. 1967; 212(2): 367-370.
23. Thulborn KR, Davis D, Adams H, Gindin T, Zhou J. Quantitative tissue sodium concentration mapping of the growth of focal cerebral tumors with sodium magnetic resonance imaging. Magn. Reson. Med. 1999; 41(2): 351-359.
24. Koch KS, Leffert HL. Increased sodium ion influx is necessary to initiate rat hepatocyte proliferation. Cell 1979; 18(1): 153-163.
25. Hodgkin AL, Huxley AF. A quantitative description of membrane current and its application to conduction and excitation in nerve. J. Physiol. 1952; 117(4): 500-544.
26. Lang F. Mechanisms and significance of cell volume regulation. J. Am. Coll. Nutr. 2007; 26(5 Suppl): 613S-623S.
27. Jain RK. Transport of molecules in the tumor interstitium: a review. Cancer Res. 1987; 47(12): 3039-3051.
28. Cameron IL, Smith NK, Pool TB, Sparks RL. Intracellular concentration of sodium and other elements as related to mitogenesis and oncogenesis in vivo. Cancer Res. 1980; 40(5): 1493-1500.
29. + ratio in human thyroid tumors. Cancer Res. 1983; 43(11): 5395-5402.
30. Thulborn KR, Davis D, Snyder J, Yonas H, Kassam A. Sodium MR imaging of acute and subacute stroke for assessment of tissue viability. Neuroimag. Clin. North Am. 2005; 15(3): 639-653.
31. Trapp BD, Stys PK. Virtual hypoxia and chronic necrosis of demyelinated axons in multiple sclerosis. Lancet Neurol. 2009; 8(3): 280-291.
32. Rush AM, Dib-Hajj SD, Waxman SG. Electrophysiological properties of two axonal sodium channels, Nav1.2 and Nav1.6, expressed in mouse spinal sensory neurones. J. Physiol. 2005; 564(Pt 3): 803-815.
33. England JD, Gamboni F, Levinson SR. Increased numbers of sodium channels form along demyelinated axons. Brain Res. 1991; 548(1-2): 334-337.
34. Waxman SG. Ions, energy and axonal injury: towards a molecular neurology of multiple sclerosis. Trends Mol. Med. 2006; 12(5): 192-195.
35. Lassmann H. Multiple sclerosis: is there neurodegeneration independent from inflammation? J. Neurol. Sci. 2007; 259(1-2): 3-6.
36. Frischer JM, Bramow S, Dal-Bianco A, Lucchinetti CF, Rauschka H, Schmidbauer M, Laursen H, Sorensen PS, Lassmann H. The relation between inflammation and neurodegeneration in multiple sclerosis brains. Brain 2009; 132(Pt 5): 1175-1189.
37. Stys PK. General mechanisms of axonal damage and its prevention. J. Neurol. Sci. 2005; 233(1-2): 3-13.
38. 2+ release in rat optic nerve during in vitro chemical ischemia. J. Neurosci. 2005; 25(43): 9960-9967.
39. Waxman SG. Conduction in myelinated, unmyelinated, and demyelinated fibers. Arch. Neurol. 1977; 34: 585-589.
40. 2+ exchanger. J. Neurosci. 1992; 12(2): 430-439.
41. Craner MJ, Damarjian TG, Liu S, Hains BC, Lo AC, Black JA, Newcombe J, Cuzner ML, Waxman SG. Sodium channels contribute to microglia/macrophage activation and function in EAE and MS. Glia 2005; 49(2): 220-229.
42. Black JA, Newcombe J, Waxman SG. Astrocytes within multiple sclerosis lesions upregulate sodium channel Nav1.5. Brain 2010; 133(Pt 3): 835-846.
43. Blokhin A, Vyshkina T, Komoly S, Kalman B. Variations in mitochondrial DNA copy numbers in MS brains. J. Mol. Neurosci. 2008; 35(3): 283-287.
44. Black JA, Dib-Hajj S, Baker D, Newcombe J, Cuzner ML, Waxman SG. Sensory neuron-specific sodium channel SNS is abnormally expressed in the brains of mice with experimental allergic encephalomyelitis and humans with multiple sclerosis. Proc. Natl. Acad. Sci. U. S. A. 2000; 97(21): 11 598-11 602.
45. Stys PK, Ransom BR, Waxman SG. Tertiary and quaternary local anesthetics protect CNS white matter from anoxic injury at concentrations that do not block excitability. J. Neurophysiol. 1992; 67(1): 236-240.
46. Stys PK, Lesiuk H. Correlation between electrophysiological effects of mexiletine and ischemic protection in central nervous system white matter. Neuroscience 1996; 71(1): 27-36.
47. Fern R, Ransom BR, Stys PK, Waxman SG. Pharmacological protection of CNS white matter during anoxia: actions of phenytoin, carbamazepine and diazepam. J. Pharmacol. Exp. Ther. 1993; 266(3): 1549-1555.
48. Stys PK. Protective effects of antiarrhythmic agents against anoxic injury in CNS white matter. J. Cereb. Blood Flow Metab. 1995; 15(3): 425-432.
49. Bechtold DA, Kapoor R, Smith KJ. Axonal protection using flecainide in experimental autoimmune encephalomyelitis. Ann. Neurol. 2004; 55(5): 607-616.
50. Lo AC, Saab CY, Black JA, Waxman SG. Phenytoin protects spinal cord axons and preserves axonal conduction and neurological function in a model of neuroinflammation in vivo. J. Neurophysiol. 2003; 90(5): 3566-3571.
51. Black JA, Liu S, Carrithers M, Carrithers LM, Waxman SG. Exacerbation of experimental autoimmune encephalomyelitis after withdrawal of phenytoin and carbamazepine. Ann. Neurol. 2007; 62(1): 21-33.
52. Bechtold DA, Miller SJ, Dawson AC, Sun Y, Kapoor R, Berry D, Smith KJ. Axonal protection achieved in a model of multiple sclerosis using lamotrigine. J. Neurol. 2006; 253(12): 1542-1551.
53. Al-Izki S, Pryce G, Hankey DJ, Lidster K, von Kutzleben SM, Browne L, Clutterbuck L, Posada C, Edith Chan AW, Amor S, Perkins V, Gerritsen WH, Ummenthum K, Peferoen-Baert R, van der Valk P, Montoya A, Joel SP, Garthwaite J, Giovannoni G, Selwood DL, Baker D. Lesional-targeting of neuroprotection to the inflammatory penumbra in experimental multiple sclerosis. Brain 2014; 137(Pt 1): 92-108.
54. Kapoor R, Furby J, Hayton T, Smith KJ, Altmann DR, Brenner R, Chataway J, Hughes RA, Miller DH. Lamotrigine for neuroprotection in secondary progressive multiple sclerosis: a randomised, double-blind, placebo-controlled, parallel-group trial. Lancet Neurol. 2010; 9(7): 681-688.
55. Friese MA, Craner MJ, Etzensperger R, Vergo S, Wemmie JA, Welsh MJ, Vincent A, Fugger L. Acid-sensing ion channel-1 contributes to axonal degeneration in autoimmune inflammation of the central nervous system. Nat. Med. 2007; 13(12): 1483-1489.
56. Vergo S, Craner MJ, Etzensperger R, Attfield K, Friese MA, Newcombe J, Esiri M, Fugger L. Acid-sensing ion channel 1 is involved in both axonal injury and demyelination in multiple sclerosis and its animal model. Brain 2011; 134(Pt 2): 571-584.
57. Arun T, Tomassini V, Sbardella E, de Ruiter MB, Matthews L, Leite MI, Gelineau-Morel R, Cavey A, Vergo S, Craner M, Fugger L, Rovira A, Jenkinson M, Palace J. Targeting ASIC1 in primary progressive multiple sclerosis: evidence of neuroprotection with amiloride. Brain 2013; 136(Pt 1): 106-115.
58. Maudsley AA, Hilal SK. Biological aspects of sodium-23 imaging. Br. Med. Bull. 1984; 40(2): 165-166.
59. 23Na MR imaging. Radiology 2003; 227(2): 529-537.
60. Mellon EA, Pilkinton DT, Clark CM, Elliott MA, Witschey WR 2nd, Borthakur A, Reddy R. Sodium MR imaging detection of mild Alzheimer disease: preliminary study. Am. J. Neuroradiol. 2009; 30(5): 978-984.
61. Inglese M, Madelin G, Oesingmann N, Babb JS, Wu W, Stoeckel B, Herbert J, Johnson G. Brain tissue sodium concentration in multiple sclerosis: a sodium imaging study at 3 tesla. Brain 2010; 133(Pt 3): 847-857.
62. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983; 33(11): 1444-1452.
63. 23Na MR imaging study. Radiology 2012; 264(3): 859-867.
64. Paling D, Solanky BS, Riemer F, Tozer DJ, Wheeler-Kingshott CA, Kapoor R, Golay X, Miller DH. Sodium accumulation is associated with disability and a progressive course in multiple sclerosis. Brain 2013; 136(Pt 7): 2305-2317.
65. Maarouf A, Audoin B, Konstandin S, Rico A, Soulier E, Reuter F, Le Troter A, Confort-Gouny S, Cozzone PJ, Guye M, Schad LR, Pelletier J, Ranjeva JP, Zaaraoui W. Topography of brain sodium accumulation in progressive multiple sclerosis. MAGMA 2014; 27(1): 53-62.
66. Fleysher L, Oesingmann N, Inglese M. B(0) inhomogeneity-insensitive triple-quantum-filtered sodium imaging using a 12-step phase-cycling scheme. NMR Biomed. 2010; 23(10): 1191-1198.
67. Fleysher L, Oesingmann N, Brown R, Sodickson DK, Wiggins GC, Inglese M. Noninvasive quantification of intracellular sodium in human brain using ultrahigh-field MRI. NMR Biomed. 2013; 26(1): 9-19.
68. Madelin G, Kline R, Walvick R, Regatte RR. A method for estimating intracellular sodium concentration and extracellular volume fraction in brain in vivo using sodium magnetic resonance imaging. Sci. Rep. 2014; 4: 4763.
69. Stobbe R, Beaulieu C. In vivo sodium magnetic resonance imaging of the human brain using soft inversion recovery fluid attenuation. Magn. Reson. Med. 2005; 54(5): 1305-1310.
70. Tsang A, Stobbe RW, Beaulieu C. Triple-quantum-filtered sodium imaging of the human brain at 4.7T. Magn. Reson. Med. 2012; 67(6): 1633-1643.
71. Tsang A, Stobbe RW, Beaulieu C. In vivo double quantum filtered sodium magnetic resonance imaging of human brain. Magn. Reson. Med. 2014; 73: 497-504.
72. 23Na NMR signal in triple quantum filtered spectra of rat hearts in the presence of shift reagents. Magn. Reson. Med. 1993; 30(4): 503-506.
73. Eliav U, Shinar H, Navon G. The formation of a 2nd-rank tensor in Na-23 double-quantum-filtered NMR as an indicator for order in a biological tissue. J. Magn. Reson. 1992; 98(1): 223-229.
74. Pekar J, Leigh JS. Detection of biexponential relaxation in Na-23 facilitated by double-quantum filtering. J. Magn. Reson. 1986; 69(3): 582-584.
75. Pekar J, Renshaw PF, Leigh JS. Selective detection of intracellular sodium by coherence-transfer NMR. J. Magn. Reson. 1987; 72(1): 159-161.
76. Paling D, Golay X, Wheeler-Kingshott C, Kapoor R, Miller D. Energy failure in multiple sclerosis and its investigation using MR techniques. J. Neurol. 2011; 258(12): 2113-2127.
77. Nikic I, Merkler D, Sorbara C, Brinkoetter M, Kreutzfeldt M, Bareyre FM, Bruck W, Bishop D, Misgeld T, Kerschensteiner M. A reversible form of axon damage in experimental autoimmune encephalomyelitis and multiple sclerosis. Nat. Med. 2011; 17(4): 495-499.